Skip to main content
Clinical Trials/NCT05330793
NCT05330793
Completed
Not Applicable

Randomized Double-blind, Placebo-controlled Trial on the Effects of an Oral Probiotic Intervention With or Without a Novel ADP-1 Toothpaste

USANA Health Sciences1 site in 1 country105 target enrollmentOctober 26, 2021
ConditionsOral Health

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Oral Health
Sponsor
USANA Health Sciences
Enrollment
105
Locations
1
Primary Endpoint
Gingival Index
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

  • Randomized double-blind, placebo-controlled trial on the effects of an oral probiotic intervention with or without a novel ADP-1 toothpaste Objective
  • Determine the safety and effectiveness of oral probiotic intervention with or without a novel toothpaste and compare with placebo

Detailed Description

Hypotheses: 1. Subjects using oral probiotics will have better oral health than subjects using placebo toothpaste and placebo lozenges. 2. Subjects using oral probiotics and ADP-1 toothpaste will have better oral health than subjects using oral probiotics and regular toothpaste, and subjects using regular toothpaste and placebo lozenges.

Registry
clinicaltrials.gov
Start Date
October 26, 2021
End Date
December 16, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
USANA Health Sciences
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ages 18 to 65 years old
  • Fluent in English
  • Have mild to moderate gingivitis (i.e., probing depth between 3mm and 5mm)
  • Bleeding on probing on 30%+ areas
  • Able to perform oral hygiene adequately after formal instructions
  • Able to understand and comply with study procedure
  • Able to provide written informed consent
  • Able to come to Roseman Dental Clinics in South Jordan for a 90-minute pre-screening to determine eligibility
  • Able to complete five (90-minute) clinic visits in 2-week intervals

Exclusion Criteria

  • • Probing depths less than 3mm
  • Breastfeeding, pregnant or trying to become pregnant
  • Currently taking or have taken any of the following within 30 days of enrollment:
  • Oral probiotics
  • Antibiotic medications
  • Antifungal medications (e.g., nystatin, clotrimazole, ketoconazole, griseofulvin)
  • Antiseptic medications
  • Immunosuppressant and/or chemotherapeutic medications
  • Medications that could affect gum response measurement (e.g., calcium channel blockers, cyclosporin, anti-seizures like phenytoin and related drugs, anti-inflammatory agents)
  • Frequent alcohol consumption (\> 2 drinks per day, or \> 8 per week for women, or \> 15 per week for men)

Outcomes

Primary Outcomes

Gingival Index

Time Frame: 8 weeks

• Gingival Index measures gingival condition of the marginal and interproximal tissues (mesial, lingual, distal, facial) separately on the basis of 0 to 3 with 0=Normal gingiva; 1= Mild inflammation - slight change in color and slight edema but no bleeding on probing; 2= Moderate inflammation - redness, edema and glazing, bleeding on probing; 3= Severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding.

Plaque Index

Time Frame: 8 weeks

• Plaque index is used as a method of recording the presence of plaque on individual tooth surfaces. These surfaces are mesial, distal, buccal and lingual.

Secondary Outcomes

  • Intraoral Imaging(8 weeks)
  • Microbial Community Analysis(8 weeks)
  • Halitosis(8 weeks)
  • SAQ(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials